SBC Medical Group Upgraded to Buy with $10 Price Target after 9% Q1 Growth
Emerging Growth Research raised SBC Medical Group to Buy and lifted its 12-month price target to $10.00 from $9.00, signaling potential upside. It noted Q1 revenue of $43.1 million with sequential growth of 9%, a $167 million cash balance, and a 13% year-over-year clinic network expansion to 284 locations.
1. Upgrade and Price Target Increase
Emerging Growth Research raised SBC Medical Group's rating to Buy and lifted the 12-month price target to $10.00 from $9.00, reflecting improved outlook following absorption of prior pricing headwinds.
2. Q1 Financial Highlights
In Q1:26, SBC reported revenue of $43.1 million, marking a 9% year-over-year decline but a 9% sequential increase; same-clinic sales rose 6% and customer visits reached 6.7 million, up 10% year-over-year with a 72% repeat rate.
3. Robust Cash Position
The company ended the quarter with approximately $167 million in cash and only modest debt, resulting in a strong net cash position relative to its market capitalization and supporting planned expansion.
4. Expansion and Growth Initiatives
SBC expanded its clinic network by 13% year-over-year to 284 locations and is targeting 1,000 clinics globally over the next nine years, while pursuing M&A in Japan, Southeast Asia and the US and investing in AI-driven operations and wellness services.